Statins for acute coronary syndrome
21 results
1 - 21
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)- Early initiation of statins following ACS does not improve outcomes
- Intensive lipid lowering reduces mortality following ACS
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Intensive lipid lowering adds additional benefit
- Overuse alert: treat-to-target LDL strategy of statin dosing is noninferior to high-intensity dosing
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Evacetrapib increases HDL but does nothing for patient-oriented outcomes
- ACC/AHA guideline for the management of patients with chronic coronary disease
- Statin therapy decreases cardiac events
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Overview of new ACC/AHA lipid guidelines: here we go again
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)